This is suggested by the results of laboratory tests conducted by the US biotechnology company after the second dose was administered to the participants in the phase 1 clinical study: the vaccination cycle induced the production of antibodies against the main viral variants, including two sub-variants of Beta ( ex South African) and the three of the Indian strain B.1.617, with a modest reduction in response compared to the original strain.

Turn on notifications to receive updates on

Moderna’s Covid vaccine induces an antibody response against the most dangerous variants of the coronavirus, including the Delta. This is indicated by the results of laboratory tests conducted by the US biotechnology company after administering the second dose to participants in the phase 1 clinical study, suggesting that even in the real world, the vaccine protects against major mutated versions of Sars-Cov-2.

The results, presented in preprint on bioXRiv show that vaccination has producedneutralizing titles against all tested variants”, including the two sub-variants of Beta (formerly South African) and the three of the Indian strain B.1.617, with a modest reduction in response compared to the original virus. Tests were also conducted against the Alpha variant (B.1.1.7, formerly English), the Eta variant (B.1.525, formerly Nigerian) and the variants A.23.1 and A.VOI.V2 identified for the first time in Uganda and Angola respectively.

The analysis was performed by evaluating the neutralizing activity of serum samples from eight study participants collected one week later having received the second dose of the vaccine, testing it against different viral variants and comparing it to the original strain (designated as D614G).

Green pass will also be used for concerts, theaters and festivals throughout Europe

Overall, the results showed that the two-dose vaccine course was much more effective at producing antibodies against the Delta variant than the Beta. Versus the three sub-variants of Beta (B.1.351-v1, B.1.351-v2, B.1.351-v3), in particular, neutralizing antibodies decreased by 6 to 8 times in comparison with those directed against the original strain, while modest reductions were observed (2.1 to 3.3 times) when compared with variants first identified in India, including Delta (B.1.617.2) e Kappa (B.1.617.1). On the other hand, the tests indicated a minimal reduction against the Alpha variant, with a decrease in the neutralization titer of 1.2 times compared to the original virus.

These new data are encouraging and reinforce our belief that the Moderna vaccine should remain protective against newly detected variants – said Stéphane Bancel, CEO of Moderna -. These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine”.

On the other hand, Moderna is also evaluating the administration of a third dose of the vaccine to strengthen the immune response against emerging variants, including a candidate of multivalent recall which combines a mix of the already approved vaccine (mRNA-1273) with an updated formulation against the South African variant (mRNA-1273.351). The trial, currently underway, has so far shown that administration significantly increases the level of antibodies against variants of concern and could be beneficial. about 6-8 months from the first vaccination course, although the antibody titers with respect to the original virus are still detectable. “As we try to defeat the pandemic, it is imperative to be proactive as the virus evolves – added Bancel -. We remain committed to studying emerging variants, generating data and sharing it as it becomes available”.

!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod?
s.parentNode.insertBefore(t,s)}(window, document,’script’,
fbq(‘init’, ‘2062554930705272’);
fbq(‘track’, ‘PageView’);
//fbq(‘track’, ‘ViewContent’);
//send custom checkpoints event
(function () {
var checkPoints = [10, 20, 40, 60, 90, 120, 180, 240, 300].sort(function(a, b) {
return a – b;
}); //seconds
var checkPointIndex = 0;
var f = function(){
var data = {
instant: checkPoints[checkPointIndex]
console.log(“[FB PIXEL] send custom event ViewContentCheckPoint “, data, ” on account ” ,”2062554930705272″ , ” currentTime in seconds “,
new Date().getTime() / 1000);
fbq(‘trackCustom’, ‘ViewContentCheckPoint’, data);
if(checkPointIndex < checkPoints.length) {
setTimeout(f, (checkPoints[checkPointIndex] – checkPoints[checkPointIndex-1]) * 1000)
setTimeout(f, checkPoints[checkPointIndex] * 1000)


Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more


The News 24 is the place where you get news about the World. we cover almost every topic so that you don’t need to find other sites.

Leave a Reply